Survey of IgG and neutralizing antibodies against SARS-CoV-2 variants in adults after vaccination

Survey of IgG and neutralizing antibodies against SARS-CoV-2 variants in adults after vaccination - Survey of IgG and neutralizing antibodies against SARS-CoV-2 variants in adults after vaccination

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045405

Enrollment

Registered

2021-09-10

Start date

2021-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Persons over 20 years old who have received two doses of Pfizer's SARS-CoV-2 vaccine and have been vaccinated for at least two weeks, and who can consent to donating a sample (30 persons) 2.Persons who participated in a clinical study prior to the COVID-19 pandemic outbreak (prior to December 2019) and who consented to their samples being used for measurements other than those in the study at that time (10 persons)

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
IgG and neutralizing antibodies against SARS-CoV-2 variants in adults after vaccination	—

Countries

Japan

Contacts

Public ContactKana Nagase

Research Center for Immunological Analysis, Inc. None

k-nagase@menekibunseki.com086-286-9333

Outcome results